創薬流通市場「薬市楽座」

安土桃山時代に自由取引市場として発展した「楽市楽座」にあやかり、創薬シーズ・技術のマーケットプラットフォームを創薬流通市場、「薬市楽座」と名付けました。このマーケットが楽市楽座のように発展することを願っています。

創薬流通市場である薬市楽座では、弊社がお預かりしている創薬シーズ・技術の情報をリストアップしています。ご興味に応じて検索していただくことが可能です。また、リストのダウンロードも行っていただけます。ご興味のあるものがあれば、お問い合わせボタンをクリックしていただき、弊社へのコンタクトをお願いいたします。追加情報を開示させていただきます。

なお、2019年6月27日より、日本語ページにおける、創薬シーズ、創薬技術の各リスト表記が英語に変更になりました。ダウンロード用のPDF、エクセルファイルは英語ページよりダウンロードできる資料と同一ですので、予めご了承下さいませ。

創薬シーズ・創薬技術一覧(PDF) 疾患領域別 創薬シーズ一覧(PDF) 創薬シーズ・創薬技術一覧(Excel)

絞り込み検索

掲載日 シーズ番号 作用機序 適応症 投与経路 モダリティ 開発ステージ 備考
21/09/17 GEM253 Influenza Virus-Neutralizing antibody Influenza i.v. Antibody Preclinical Neutralizing activity against Influenza virus, human H1N1, H2N2, H3N2, H5N1, and avian H3N8.
Passive immunization with the pan-neutralizing antibody enables to effectively prevent or treat influenza even in the event of an antigenic shift, as well as an antigenic drift.
問合せ
21/09/14 GEM252 Cultured skin stem cells autografts Spinal cord injury Trans-plant into spinal cord (Auto-logus) Cell therapy Clinical application finished The Skin stem cells cultured in serum-free medium express Nestin, CD73, and GDNF. They showed no tumorigenicity in carcinogenicity test. Autologous transplantation for patients with spinal cord injury was performed with intraspinal administration via lumbar puncture. A most aggressive result was a case which a man with 2.5years paralysis of lower limbs by Th3 site injury, who recovered to the level of walking after receiving 2 times. 問合せ
21/09/08 GEM251 Antisense oligo nucleotide (ASO) suppressing the expression of human p53 gene AKI(acute kidney injury), Heart failure, Stroke i.v. Nucleic acid Discovery/ Preclinical Same as GEM248 問合せ
21/09/08 GEM250 Antisense oligo nucleotide (ASO) suppressing the expression of human p53 gene Drug-induced alopecia Topical Nucleic acid Discovery Same as GEM248 問合せ
21/09/08 GEM249 Antisense oligo nucleotide (ASO) suppressing the expression of human p53 gene Sensorineural Hearing Loss Topical Nucleic acid Discovery Same as GEM248 問合せ
21/09/08 GEM248 Antisense oligo nucleotide (ASO) suppressing the expression of human p53 gene ALS(C9orf72) Intraーmedullary Nucleic acid Discovery Suppression of p53 expression may reduce the tissue damage and enhance tissue repair in several disease conditions. It inhibits p53 expression better than the competitor compound in cultured cell, and is therefore expected to be highly effective in clinical practice. 問合せ
21/08/25 GEM247 Activation of progenitor and endothelial progenitor cells Chronic limb threatening ischemia Injection and device Regenerative therapy Clinical Regenerative therapy for vascular disease promotes new vessel growth. Excellent clinical results include pain relief, wound healing, hemodynamic improvement, new collaterals visible on angiography, biochemical support for mechanism of action, and limb salvage. 問合せ
21/08/18 GEM246 Anti-SARS-Cov-2 IgY antibody COVID-19 Intra-nasal or inhalation Antibody Preclinical ・IgY antibody extracted from egg yolk of hens immunized with SARS- Cov-2 virus
・The highest concentration of antibodies in the animal kingdom is found in a single egg yolk
・Faster and lower cost in manufacturing vs monoclonal antibody
・Could be used for both therapeutic and prophylactic purposes (passive immunization)
・Looking for partner in Japan
問合せ
21/06/04 GEM185 GLP-1/GIP dual agonist Obesity, diabetes s.c. Peptide Phase 1 GEM185 is an injectable (QD) dual agonist for GLP-1R and GIPR. Preclinical studies have shown that GEM185 is more effective in improving diabetes and obesity than GLP-1R agonism only. In addition, GEM185 has been shown to improve liver parameters in diabetic and obesity conditions in preclinical research. Hence, GEM185 may be superior to the GLP-1R agonist in improving diabetes, obesity, and non-alcoholic steatohepatitis (NASH). In a preclinical study, GEM185 showed better efficacy in improving glycemic control and an almost same efficacy in decreasing body weight compared to tirzepatide, a Lilly’s Ph3 program. A long-acting formulation, which is likely to maximize its therapeutic efficacy, are under development. A phase 1 study (first-in-human study) started in 2020 in the UK. No longer available for licensing to Asia/Pacific excluding Japan. 問合せ
21/06/02 GEM245 Recombinant protein based on complement inhibitor C4BP with anti-inflammatory and tolerogenic action Autoimmune diseases including SLE, IBD and RA s.c. injection Protein Preclinical (before GLP) ・Recombinant protein based on endogenous complement inhibitor C4BP exerts anti-inflammatory and tolerogenic action on dendritic cells.
・A novel biologic for immunomodulation, not immunosuppression.
・Reduces TLR-induced overproduction of proinflammatory cytokines (IL-12, TNF-alpha, IFN-gamma).
・Confirmed in vivo efficacy in SLE model, RA model, and DSS-induced colitis model.
・Global IP coverage (incl. compositions)
問合せ